blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3581245

EP3581245 - ANTIBODIES TO TAU AND USES THEREOF [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  24.11.2023
Database last updated on 07.10.2024
FormerGrant of patent is intended
Status updated on  19.07.2023
FormerExamination is in progress
Status updated on  05.06.2023
FormerGrant of patent is intended
Status updated on  05.02.2023
FormerExamination is in progress
Status updated on  04.09.2020
FormerRequest for examination was made
Status updated on  26.06.2020
FormerThe application has been published
Status updated on  15.11.2019
Most recent event   Tooltip03.10.2024Lapse of the patent in a contracting state
New state(s): MC		published on 06.11.2024 [2024/45]
Applicant(s)For all designated states
ELI LILLY AND COMPANY
Lilly Corporate Center
Indianapolis, IN 46285 / US
[2022/04]
Former [2019/51]For all designated states
ELI LILLY AND CO.
Lilly Corporate Center
Indianapolis, IN 46285 / US
Inventor(s)01 / Alvarado, Alberto
c/o Eli Lilly and Company
P.O. Box 6288
Indianapolis, Indiana 46206-6288 / US
02 / Driver, David
c/o Eli Lilly and Company
P.O. Box 6288
Indianapolise, Indiana 46206-6288 / US
03 / Hayashi, Mansuo Lu
c/o Eli Lilly and Company
P.O. Box 6288
Indianapolis, Indiana 46206-6288 / US
04 / Lu, Jirong
c/o Eli Lilly and Company
P.O. Box 6288
Indianapolis, Indiana 46206-6288 / US
 [2019/51]
Representative(s)Boanas-Evans, Duncan Richard
Eli Lilly and Company Limited
8 Arlington Square West
Downshire Way
Bracknell, Berkshire RG12 1PU / GB
[N/P]
Former [2023/52]Kent, Lindsey Ruth
Eli Lilly and Company Limited
8 Arlington Square West Downshire Way
Bracknell, Berkshire RG12 1PU / GB
Former [2019/51]Kent, Lindsey Ruth
Eli Lilly and Company Limited
Lilly Research Center
Erl Wood Manor
Sunninghill Road, Windlesham
Surrey GU20 6PH / GB
Application number, filing date19184449.718.02.2016
[2019/51]
Priority number, dateUS201562121116P26.02.2015         Original published format: US 201562121116 P
[2019/51]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3581245
Date:18.12.2019
Language:EN
[2019/51]
Type: B1 Patent specification 
No.:EP3581245
Date:27.12.2023
Language:EN
[2023/52]
Search report(s)(Supplementary) European search report - dispatched on:EP07.11.2019
ClassificationIPC:A61P25/28, A61K39/00, C07K16/18
[2019/51]
CPC:
C07K16/18 (EP,CN,IL,KR,US); A61K49/16 (US); A61P25/00 (EP);
A61P25/28 (EP); C07K16/00 (US); C12N15/00 (US);
C12N15/09 (US); C12N15/10 (US); A01K2267/0318 (US);
A61K2039/505 (EP,CN,IL,KR,US); A61K39/0005 (US); A61K39/0007 (US);
A61K39/395 (US); A61K39/3955 (US); A61K45/06 (US);
A61K49/0058 (US); A61K51/1018 (US); C07H21/00 (US);
C07H21/04 (US); C07K14/435 (US); C07K14/47 (US);
C07K14/4711 (US); C07K2317/21 (US); C07K2317/24 (EP,IL,KR,US);
C07K2317/34 (IL,KR,US); C07K2317/51 (IL,KR,US); C07K2317/515 (IL,KR,US);
C07K2317/52 (KR,US); C07K2317/565 (EP,IL,KR,US); C07K2317/567 (EP,KR,US);
C07K2317/622 (US); C07K2317/76 (EP,CN,IL,KR,US); C07K2317/90 (KR);
C07K2317/92 (EP,CN,IL,US); C07K2317/94 (EP,CN,IL,US); C12N5/06 (US);
C12N5/0602 (US); C12P21/00 (US); C12P21/02 (US);
G01N2800/28 (US); G01N2800/2814 (US); G01N2800/2821 (US);
G01N2800/52 (US); G01N2800/56 (US); G01N33/573 (US);
G01N33/577 (US); G01N33/6854 (US); G01N33/6896 (US);
Y10S424/80 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/31]
Former [2019/51]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:ANTIKÖRPER GEGEN TAU UND VERWENDUNGEN DAVON[2019/51]
English:ANTIBODIES TO TAU AND USES THEREOF[2019/51]
French:ANTICORPS POUR TAU ET UTILISATIONS ASSOCIÉES[2019/51]
Examination procedure18.06.2020Amendment by applicant (claims and/or description)
18.06.2020Examination requested  [2020/31]
18.06.2020Date on which the examining division has become responsible
04.09.2020Despatch of a communication from the examining division (Time limit: M04)
07.01.2021Reply to a communication from the examining division
17.03.2021Despatch of a communication from the examining division (Time limit: M06)
24.09.2021Reply to a communication from the examining division
06.02.2023Communication of intention to grant the patent
02.06.2023Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
20.07.2023Communication of intention to grant the patent
16.11.2023Fee for grant paid
16.11.2023Fee for publishing/printing paid
16.11.2023Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP16706741.2  / EP3261720
Fees paidRenewal fee
04.11.2019Renewal fee patent year 03
04.11.2019Renewal fee patent year 04
02.03.2020Renewal fee patent year 05
01.03.2021Renewal fee patent year 06
28.02.2022Renewal fee patent year 07
28.02.2023Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT27.12.2023
CZ27.12.2023
EE27.12.2023
FI27.12.2023
HR27.12.2023
LT27.12.2023
LV27.12.2023
MC27.12.2023
NL27.12.2023
PL27.12.2023
RO27.12.2023
RS27.12.2023
SE27.12.2023
SK27.12.2023
SM27.12.2023
BG27.03.2024
NO27.03.2024
GR28.03.2024
IS27.04.2024
PT29.04.2024
[2024/45]
Former [2024/36]AT27.12.2023
CZ27.12.2023
EE27.12.2023
FI27.12.2023
HR27.12.2023
LT27.12.2023
LV27.12.2023
NL27.12.2023
PL27.12.2023
RO27.12.2023
RS27.12.2023
SE27.12.2023
SK27.12.2023
SM27.12.2023
BG27.03.2024
NO27.03.2024
GR28.03.2024
IS27.04.2024
PT29.04.2024
Former [2024/35]AT27.12.2023
CZ27.12.2023
EE27.12.2023
FI27.12.2023
HR27.12.2023
LT27.12.2023
LV27.12.2023
NL27.12.2023
RO27.12.2023
RS27.12.2023
SE27.12.2023
SM27.12.2023
BG27.03.2024
NO27.03.2024
GR28.03.2024
IS27.04.2024
Former [2024/34]EE27.12.2023
FI27.12.2023
HR27.12.2023
LT27.12.2023
LV27.12.2023
NL27.12.2023
RS27.12.2023
SE27.12.2023
SM27.12.2023
BG27.03.2024
NO27.03.2024
GR28.03.2024
IS27.04.2024
Former [2024/33]FI27.12.2023
HR27.12.2023
LT27.12.2023
LV27.12.2023
NL27.12.2023
RS27.12.2023
SE27.12.2023
SM27.12.2023
BG27.03.2024
NO27.03.2024
GR28.03.2024
IS27.04.2024
Former [2024/32]FI27.12.2023
HR27.12.2023
LT27.12.2023
LV27.12.2023
NL27.12.2023
RS27.12.2023
SE27.12.2023
BG27.03.2024
NO27.03.2024
GR28.03.2024
IS27.04.2024
Former [2024/26]FI27.12.2023
HR27.12.2023
LT27.12.2023
LV27.12.2023
NL27.12.2023
RS27.12.2023
SE27.12.2023
BG27.03.2024
NO27.03.2024
GR28.03.2024
Former [2024/25]FI27.12.2023
HR27.12.2023
LT27.12.2023
RS27.12.2023
SE27.12.2023
BG27.03.2024
NO27.03.2024
GR28.03.2024
Former [2024/21]FI27.12.2023
LT27.12.2023
BG27.03.2024
GR28.03.2024
Former [2024/20]GR28.03.2024
Documents cited:Search[IA]WO2012149365  (UNIV NORTHWESTERN [US], et al);
 [IA]WO2014059442  (ARIZONA BOARD AGENTS A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA ST [US], et al);
 [IA]WO2014100600  (BIOGEN IDEC INC [US], et al);
by applicantWO2011026031
 WO2012049570
 WO2013050567
 US8926974
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.